BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hong DS, Fakih MG, Strickler JH, Desai J, Durm GA, Shapiro GI, Falchook GS, Price TJ, Sacher A, Denlinger CS, Bang YJ, Dy GK, Krauss JC, Kuboki Y, Kuo JC, Coveler AL, Park K, Kim TW, Barlesi F, Munster PN, Ramalingam SS, Burns TF, Meric-Bernstam F, Henary H, Ngang J, Ngarmchamnanrith G, Kim J, Houk BE, Canon J, Lipford JR, Friberg G, Lito P, Govindan R, Li BT. KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors. N Engl J Med 2020;383:1207-17. [PMID: 32955176 DOI: 10.1056/NEJMoa1917239] [Cited by in Crossref: 203] [Cited by in F6Publishing: 121] [Article Influence: 101.5] [Reference Citation Analysis]
Number Citing Articles
1 Krishnan T, Roberts-Thomson R, Broadbridge V, Price T. Targeting Mutated KRAS Genes to Treat Solid Tumours. Mol Diagn Ther 2021. [PMID: 34914038 DOI: 10.1007/s40291-021-00564-0] [Reference Citation Analysis]
2 Cheng WL, Feng PH, Lee KY, Chen KY, Sun WL, Van Hiep N, Luo CS, Wu SM. The Role of EREG/EGFR Pathway in Tumor Progression. Int J Mol Sci 2021;22:12828. [PMID: 34884633 DOI: 10.3390/ijms222312828] [Reference Citation Analysis]
3 Li J, Ma X, Chakravarti D, Shalapour S, DePinho RA. Genetic and biological hallmarks of colorectal cancer. Genes Dev 2021;35:787-820. [PMID: 34074695 DOI: 10.1101/gad.348226.120] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Boehm JS, Garnett MJ, Adams DJ, Francies HE, Golub TR, Hahn WC, Iorio F, McFarland JM, Parts L, Vazquez F. Cancer research needs a better map. Nature 2021;589:514-6. [PMID: 33500573 DOI: 10.1038/d41586-021-00182-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
5 Koch PD, Quintana J, Ahmed M, Kohler RH, Weissleder R. SMALL MOLECULE IMAGING AGENT FOR MUTANT KRAS G12C. Adv Ther (Weinh) 2021;4:2000290. [PMID: 33997272 DOI: 10.1002/adtp.202000290] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Simbolo M, Centonze G, Ali G, Garzone G, Taormina S, Sabella G, Ciaparrone C, Mafficini A, Grillo F, Mangogna A, Volante M, Mastracci L, Fontanini G, Pilotto S, Bria E, Infante M, Capella C, Rolli L, Pastorino U, Milella M, Milione M, Scarpa A. Integrative molecular analysis of combined small-cell lung carcinomas identifies major subtypes with different therapeutic opportunities. ESMO Open 2022;7:100308. [DOI: 10.1016/j.esmoop.2021.100308] [Reference Citation Analysis]
7 Ruiz-Patiño A, Rodríguez J, Cardona AF, Ávila J, Archila P, Carranza H, Vargas C, Otero J, Arrieta O, Zatarain-Barrón L, Sotelo C, Ordoñez C, García-Robledo JE, Rojas L, Bermúdez M, Gámez T, Mayorga D, Corrales L, Martín C, Recondo G, Mas L, Samtani S, Ricaurte L, Malapelle U, Russo A, Barrón F, Santoyo N, Rolfo C, Rosell R; ONCOLGroup., CLICaP. p.G12C KRAS mutation prevalence in non-small cell lung cancer: Contribution from interregional variability and population substructures among Hispanics. Transl Oncol 2022;15:101276. [PMID: 34823093 DOI: 10.1016/j.tranon.2021.101276] [Reference Citation Analysis]
8 Kim SI, Cassella CR, Byrne KT. Tumor Burden and Immunotherapy: Impact on Immune Infiltration and Therapeutic Outcomes. Front Immunol 2020;11:629722. [PMID: 33597954 DOI: 10.3389/fimmu.2020.629722] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
9 Kastrisiou M, Zarkavelis G, Kougioumtzi A, Sakaloglou P, Kostoulas C, Georgiou I, Batistatou A, Pentheroudakis G, Magklara A. Development and Validation of a Targeted ‘Liquid’ NGS Panel for Treatment Customization in Patients with Metastatic Colorectal Cancer. Diagnostics 2021;11:2375. [DOI: 10.3390/diagnostics11122375] [Reference Citation Analysis]
10 Chang L, Ruiz P, Ito T, Sellers WR. Targeting pan-essential genes in cancer: Challenges and opportunities. Cancer Cell 2021;39:466-79. [PMID: 33450197 DOI: 10.1016/j.ccell.2020.12.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
11 Wahl SGF, Dai HY, Emdal EF, Berg T, Halvorsen TO, Ottestad AL, Lund-Iversen M, Brustugun OT, Førde D, Paulsen EE, Donnem T, Andersen S, Grønberg BH, Richardsen E. The Prognostic Effect of KRAS Mutations in Non-Small Cell Lung Carcinoma Revisited: A Norwegian Multicentre Study. Cancers (Basel) 2021;13:4294. [PMID: 34503114 DOI: 10.3390/cancers13174294] [Reference Citation Analysis]
12 Blaquier JB, Cardona AF, Recondo G. Resistance to KRASG12C Inhibitors in Non-Small Cell Lung Cancer. Front Oncol 2021;11:787585. [PMID: 35004309 DOI: 10.3389/fonc.2021.787585] [Reference Citation Analysis]
13 Baltanás FC, García-Navas R, Santos E. SOS2 Comes to the Fore: Differential Functionalities in Physiology and Pathology. Int J Mol Sci 2021;22:6613. [PMID: 34205562 DOI: 10.3390/ijms22126613] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Burns EA, Ensor JE, Hsu J, Thomas JS, Olsen RJ, Bernicker EH. Outcomes and prognostic contributors in patients with KRAS mutated non-small cell pulmonary adenocarcinomas: a single institution experience. J Thorac Dis 2021;13:4785-96. [PMID: 34527319 DOI: 10.21037/jtd-21-432] [Reference Citation Analysis]
15 Kong F, Wang Z, Liao D, Zuo J, Xie H, Li X, Jia Y. Non-Small Cell Lung Cancer: Challenge and Improvement of Immune Drug Resistance. Front Oncol 2021;11:739191. [PMID: 34532293 DOI: 10.3389/fonc.2021.739191] [Reference Citation Analysis]
16 Reggiani F, Sauta E, Torricelli F, Zanetti E, Tagliavini E, Santandrea G, Gobbi G, Damia G, Bellazzi R, Ambrosetti D, Ciarrocchi A, Sancisi V. An integrative functional genomics approach reveals EGLN1 as a novel therapeutic target in KRAS mutated lung adenocarcinoma. Mol Cancer 2021;20:63. [PMID: 33823854 DOI: 10.1186/s12943-021-01357-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Asimgil H, Ertetik U, Çevik NC, Ekizce M, Doğruöz A, Gökalp M, Arık-Sever E, Istvanffy R, Friess H, Ceyhan GO, Demir IE. Targeting the undruggable oncogenic KRAS: the dawn of hope. JCI Insight 2022;7:e153688. [PMID: 35014625 DOI: 10.1172/jci.insight.153688] [Reference Citation Analysis]
18 Vanacker H, Cassier PA, Bachelot T. The complex balance of PI3K inhibition. Ann Oncol 2021;32:127-8. [PMID: 33272746 DOI: 10.1016/j.annonc.2020.10.597] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Chevallier M, Borgeaud M, Addeo A, Friedlaender A. Oncogenic driver mutations in non-small cell lung cancer: Past, present and future . World J Clin Oncol 2021; 12(4): 217-237 [PMID: 33959476 DOI: 10.5306/wjco.v12.i4.217] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
20 Pfeiffer P, Qvortrup C. KRASG12C inhibition in colorectal cancer. Lancet Oncol 2022;23:10-1. [PMID: 34919826 DOI: 10.1016/S1470-2045(21)00652-5] [Reference Citation Analysis]
21 Osaka N, Hirota Y, Ito D, Ikeda Y, Kamata R, Fujii Y, Chirasani VR, Campbell SL, Takeuchi K, Senda T, Sasaki AT. Divergent Mechanisms Activating RAS and Small GTPases Through Post-translational Modification. Front Mol Biosci 2021;8:707439. [PMID: 34307463 DOI: 10.3389/fmolb.2021.707439] [Reference Citation Analysis]
22 Carr RM, Jin Z, Hubbard J. Research on Anal Squamous Cell Carcinoma: Systemic Therapy Strategies for Anal Cancer. Cancers (Basel) 2021;13:2180. [PMID: 34062753 DOI: 10.3390/cancers13092180] [Reference Citation Analysis]
23 Aleksakhina SN, Imyanitov EN. Cancer Therapy Guided by Mutation Tests: Current Status and Perspectives. Int J Mol Sci 2021;22:10931. [PMID: 34681592 DOI: 10.3390/ijms222010931] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Rogers JE, Dasari A. Pharmacotherapy for unresectable metastatic colorectal cancer. Expert Opin Pharmacother 2021;:1-10. [PMID: 34534031 DOI: 10.1080/14656566.2021.1982895] [Reference Citation Analysis]
25 Losmanova T, Zens P, Scherz A, Schmid RA, Tschan MP, Berezowska S. Chaperone-Mediated Autophagy Markers LAMP2A and HSPA8 in Advanced Non-Small Cell Lung Cancer after Neoadjuvant Therapy. Cells 2021;10:2731. [PMID: 34685711 DOI: 10.3390/cells10102731] [Reference Citation Analysis]
26 Rekhtman N. Lung neuroendocrine neoplasms: recent progress and persistent challenges. Mod Pathol 2021. [PMID: 34663914 DOI: 10.1038/s41379-021-00943-2] [Reference Citation Analysis]
27 Ferrara MG, Stefani A, Pilotto S, Carbone C, Vita E, Di Salvatore M, D'Argento E, Sparagna I, Monaca F, Valente G, Vitale A, Piro G, Belluomini L, Milella M, Tortora G, Bria E. The Renaissance of KRAS Targeting in Advanced Non-Small-Cell Lung Cancer: New Opportunities Following Old Failures. Front Oncol 2021;11:792385. [PMID: 35004317 DOI: 10.3389/fonc.2021.792385] [Reference Citation Analysis]
28 Garcia-Alvarez A, Ortiz C, Muñoz-Couselo E. Current Perspectives and Novel Strategies of NRAS-Mutant Melanoma. Onco Targets Ther 2021;14:3709-19. [PMID: 34135599 DOI: 10.2147/OTT.S278095] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Pujol JL, Vansteenkiste J, Paz-Ares Rodríguez L, Gregorc V, Mazieres J, Awad M, Jänne PA, Chisamore M, Hossain AM, Chen Y, Beck JT. Abemaciclib in Combination With Pembrolizumab for Stage IV KRAS-Mutant or Squamous NSCLC: A Phase 1b Study. JTO Clin Res Rep 2021;2:100234. [PMID: 34746886 DOI: 10.1016/j.jtocrr.2021.100234] [Reference Citation Analysis]
30 Bauml JM, Li BT, Velcheti V, Govindan R, Curioni-Fontecedro A, Dooms C, Takahashi T, Duda AW, Odegaard JI, Cruz-Guilloty F, Jin L, Zhang Y, Anderson A, Skoulidis F. Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib. Lung Cancer 2021:S0169-5002(21)00578-X. [PMID: 34838325 DOI: 10.1016/j.lungcan.2021.10.007] [Reference Citation Analysis]
31 de la Fouchardière C, Wassermann J, Calcagno F, Bardet S, Al Ghuzlan A, Borget I, Borson Chazot F, Do Cao C, Buffet C, Zerdoud S, Decaussin-Petrucci M, Godbert Y, Leboulleux S. [Molecular genotyping in refractory thyroid cancers in 2021: When, how and why? A review from the TUTHYREF network]. Bull Cancer 2021;108:1044-56. [PMID: 34593218 DOI: 10.1016/j.bulcan.2021.06.009] [Reference Citation Analysis]
32 Zhang B, Zhang Y, Zhang J, Liu P, Jiao B, Wang Z, Ren R. Focal Adhesion Kinase (FAK) Inhibition Synergizes with KRAS G12C Inhibitors in Treating Cancer through the Regulation of the FAK-YAP Signaling. Adv Sci (Weinh) 2021;8:e2100250. [PMID: 34151545 DOI: 10.1002/advs.202100250] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 Gu M, Gao Y, Chang P. KRAS Mutation Dictates the Cancer Immune Environment in Pancreatic Ductal Adenocarcinoma and Other Adenocarcinomas. Cancers (Basel) 2021;13:2429. [PMID: 34069772 DOI: 10.3390/cancers13102429] [Reference Citation Analysis]
34 Kemper M, Evers G, Schulze AB, Sperveslage J, Schülke C, Lenz G, Herold T, Hartmann W, Schildhaus HU, Bleckmann A. Polyclonal on- and off-target resistance mutations in an EML4-ALK positive non-small cell lung cancer patient under ALK inhibition. Oncotarget 2021;12:1946-52. [PMID: 34548910 DOI: 10.18632/oncotarget.28062] [Reference Citation Analysis]
35 Kadakia KT, Halperin DM, Offodile AC 2nd. Operationalizing Virtual Trials in Oncology-From Aspiration to Action. JCO Clin Cancer Inform 2021;5:953-7. [PMID: 34516277 DOI: 10.1200/CCI.21.00073] [Reference Citation Analysis]
36 Sayama H, Marcantonio D, Nagashima T, Shimazaki M, Minematsu T, Apgar JF, Burke JM, Wille L, Nagasaka Y, Kirouac DC. Virtual clinical trial simulations for a novel KRASG12C inhibitor (ASP2453) in non-small cell lung cancer. CPT Pharmacometrics Syst Pharmacol 2021;10:864-77. [PMID: 34043291 DOI: 10.1002/psp4.12661] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
37 Grant MJ, Herbst RS, Goldberg SB. Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC. Nat Rev Clin Oncol 2021. [PMID: 34168333 DOI: 10.1038/s41571-021-00520-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
38 Okutachi S, Manoharan GB, Kiriazis A, Laurini C, Catillon M, McCormick F, Yli-Kauhaluoma J, Abankwa D. A Covalent Calmodulin Inhibitor as a Tool to Study Cellular Mechanisms of K-Ras-Driven Stemness. Front Cell Dev Biol 2021;9:665673. [PMID: 34307350 DOI: 10.3389/fcell.2021.665673] [Reference Citation Analysis]
39 Schlick K, Kiem D, Greil R. Recent Advances in Pancreatic Cancer: Novel Prognostic Biomarkers and Targeted Therapy-A Review of the Literature. Biomolecules 2021;11:1469. [PMID: 34680101 DOI: 10.3390/biom11101469] [Reference Citation Analysis]
40 Soulières D, Gelmon KA. Sotorasib: Is Maximum Tolerated Dose Really the Issue at Hand? J Clin Oncol 2021;39:3427-9. [PMID: 34543060 DOI: 10.1200/JCO.21.02072] [Reference Citation Analysis]
41 Tartarone A, Lapadula V, Di Micco C, Rossi G, Ottanelli C, Marini A, Giorgione R, Ferrari K, Catalano M, Voltolini L, Mini E, Roviello G. Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer. Front Oncol 2021;11:632256. [PMID: 34094913 DOI: 10.3389/fonc.2021.632256] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Prelaj A, Pircher CC, Massa G, Martelli V, Corrao G, Lo Russo G, Proto C, Ferrara R, Galli G, De Toma A, Genova C, Jereczek-Fossa BA, Braud F, Garassino MC, Rebuzzi SE. Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and Systemic Progression. Cancers (Basel) 2021;13:1300. [PMID: 33803958 DOI: 10.3390/cancers13061300] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
43 van 't Erve I, Wesdorp NJ, Medina JE, Ferreira L, Leal A, Huiskens J, Bolhuis K, van Waesberghe JTM, Swijnenburg RJ, van den Broek D, Velculescu VE, Kazemier G, Punt CJA, Meijer GA, Fijneman RJA. KRAS A146 Mutations Are Associated With Distinct Clinical Behavior in Patients With Colorectal Liver Metastases. JCO Precis Oncol 2021;5:PO. [PMID: 34820593 DOI: 10.1200/PO.21.00223] [Reference Citation Analysis]
44 Liu S, Medina-Perez P, Ha-Thi MC, Wieland A, Stecklum M, Hoffmann J, Tchernitsa O, Sers C, Schäfer R. Rapid testing of candidate oncogenes and tumour suppressor genes in signal transduction and neoplastic transformation. Adv Biol Regul 2021;:100841. [PMID: 34866037 DOI: 10.1016/j.jbior.2021.100841] [Reference Citation Analysis]
45 Liu Y, Wu L, Lu H, Wu E, Ni J, Zhou X. Enhancing the Therapeutic Efficacy of KRASG12C Inhibitors in Lung Adenocarcinoma Cell Models by Cotargeting the MAPK Pathway or HSP90. J Oncol 2021;2021:2721466. [PMID: 34858498 DOI: 10.1155/2021/2721466] [Reference Citation Analysis]
46 Kyriakopoulos G, Katopodi V, Skeparnias I, Kaliatsi EG, Grafanaki K, Stathopoulos C. KRASG12C Can Either Promote or Impair Cap-Dependent Translation in Two Different Lung Adenocarcinoma Cell Lines. Int J Mol Sci 2021;22:2222. [PMID: 33672357 DOI: 10.3390/ijms22042222] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Zhang T, Xu Z, Liu G, Jiang B, de Bock GH, Groen HJM, Vliegenthart R, Xie X. Simultaneous Identification of EGFR,KRAS,ERBB2, and TP53 Mutations in Patients with Non-Small Cell Lung Cancer by Machine Learning-Derived Three-Dimensional Radiomics. Cancers (Basel) 2021;13:1814. [PMID: 33920322 DOI: 10.3390/cancers13081814] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Ning W, Yang Z, Kocher GJ, Dorn P, Peng R. A Breakthrough Brought about by Targeting KRASG12C: Nonconformity Is Punished. Cancers 2022;14:390. [DOI: 10.3390/cancers14020390] [Reference Citation Analysis]
49 Kemps PG, Bol M, Steller EJA, de Pont LMH, Holterhues C, van Gerven L, Kolkman W. Colon carcinoma presenting as ovarian metastasis. Radiol Case Rep 2021;16:2799-803. [PMID: 34367398 DOI: 10.1016/j.radcr.2021.06.072] [Reference Citation Analysis]
50 König D, Savic Prince S, Rothschild SI. Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations. Cancers (Basel) 2021;13:804. [PMID: 33671873 DOI: 10.3390/cancers13040804] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
51 Tonse R, Rubens M, Appel H, Tom MC, Hall MD, Odia Y, Mcdermott MW, Ahluwalia MS, Mehta MP, Kotecha R. Systematic review and meta-analysis of lung cancer brain metastasis and primary tumor receptor expression discordance. Discov Onc 2021;12. [DOI: 10.1007/s12672-021-00445-2] [Reference Citation Analysis]
52 Ursu O, Neal JT, Shea E, Thakore PI, Jerby-arnon L, Nguyen L, Dionne D, Diaz C, Bauman J, Mosaad MM, Fagre C, Lo A, Mcsharry M, Giacomelli AO, Ly SH, Rozenblatt-rosen O, Hahn WC, Aguirre AJ, Berger AH, Regev A, Boehm JS. Massively parallel phenotyping of coding variants in cancer with Perturb-seq. Nat Biotechnol. [DOI: 10.1038/s41587-021-01160-7] [Reference Citation Analysis]
53 Sunaga N, Miura Y, Kasahara N, Sakurai R. Targeting Oncogenic KRAS in Non-Small-Cell Lung Cancer. Cancers (Basel) 2021;13:5956. [PMID: 34885068 DOI: 10.3390/cancers13235956] [Reference Citation Analysis]
54 Yachida N, Yoshihara K, Suda K, Nakaoka H, Ueda H, Sugino K, Yamaguchi M, Mori Y, Yamawaki K, Tamura R, Ishiguro T, Kase H, Motoyama T, Enomoto T. Biological significance of KRAS mutant allele expression in ovarian endometriosis. Cancer Sci 2021;112:2020-32. [PMID: 33675098 DOI: 10.1111/cas.14871] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
55 Plangger A, Rath B, Hochmair M, Funovics M, Hamilton G. Cytotoxicity of combinations of the pan-KRAS inhibitor BAY-293 against primary non-small lung cancer cells. Transl Oncol 2021;14:101230. [PMID: 34598083 DOI: 10.1016/j.tranon.2021.101230] [Reference Citation Analysis]
56 Ulmer B, Odenthal M, Buettner R, Roth W, Kloth M. Diffusion kernel-based predictive modeling of KRAS dependency in KRAS wild type cancer cell lines. NPJ Syst Biol Appl 2022;8:2. [PMID: 35046405 DOI: 10.1038/s41540-021-00211-8] [Reference Citation Analysis]
57 Huerta M, Roselló S, Sabater L, Ferrer A, Tarazona N, Roda D, Gambardella V, Alfaro-Cervelló C, Garcés-Albir M, Cervantes A, Ibarrola-Villava M. Circulating Tumor DNA Detection by Digital-Droplet PCR in Pancreatic Ductal Adenocarcinoma: A Systematic Review. Cancers (Basel) 2021;13:994. [PMID: 33673558 DOI: 10.3390/cancers13050994] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
58 Rebuzzi SE, Zullo L, Rossi G, Grassi M, Murianni V, Tagliamento M, Prelaj A, Coco S, Longo L, Dal Bello MG, Alama A, Dellepiane C, Bennicelli E, Malapelle U, Genova C. Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer. Int J Mol Sci 2021;22:2625. [PMID: 33807876 DOI: 10.3390/ijms22052625] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
59 Baraibar I, Mirallas O, Saoudi N, Ros J, Salvà F, Tabernero J, Élez E. Combined Treatment with Immunotherapy-Based Strategies for MSS Metastatic Colorectal Cancer. Cancers (Basel) 2021;13:6311. [PMID: 34944931 DOI: 10.3390/cancers13246311] [Reference Citation Analysis]
60 Zhang SS, Nagasaka M. Spotlight on Sotorasib (AMG 510) for KRAS G12C Positive Non-Small Cell Lung Cancer. Lung Cancer (Auckl) 2021;12:115-22. [PMID: 34675734 DOI: 10.2147/LCTT.S334623] [Reference Citation Analysis]
61 Naim N, Moukheiber S, Jaber K, Kourie HR. After decades, RAS mutation has finally become a therapeutic target. Per Med 2021;18:523-5. [PMID: 34657456 DOI: 10.2217/pme-2021-0015] [Reference Citation Analysis]
62 Indini A, Rijavec E, Ghidini M, Cortellini A, Grossi F. Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors. Pharmaceutics 2021;13:653. [PMID: 34064352 DOI: 10.3390/pharmaceutics13050653] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
63 Köhler J, Jänne PA. If Virchow and Ehrlich Had Dreamt Together: What the Future Holds for KRAS-Mutant Lung Cancer. Int J Mol Sci 2021;22:3025. [PMID: 33809660 DOI: 10.3390/ijms22063025] [Reference Citation Analysis]
64 Fernández-Medarde A, Fuentes-Mateos R, García-Navas R, Juan AO, Sánchez-López JM, Fernández-Medarde A, Santos E. Anthraquinones as Inhibitors of SOS RAS-GEF Activity. Biomolecules 2021;11:1128. [PMID: 34439794 DOI: 10.3390/biom11081128] [Reference Citation Analysis]
65 Elbanna M, Chowdhury NN, Rhome R, Fishel ML. Clinical and Preclinical Outcomes of Combining Targeted Therapy With Radiotherapy. Front Oncol 2021;11:749496. [PMID: 34733787 DOI: 10.3389/fonc.2021.749496] [Reference Citation Analysis]
66 Murakami N, Asami Y, Yoshida H, Takayanagi D, Hirose S, Kuno I, Takahashi K, Matsuda M, Shimada Y, Yamano S, Sunami K, Honda T, Nakahara T, Watanabe T, Okuma K, Kuroda T, Kohno T, Kato T, Shiraishi K, Itami J. Distribution of genetic alterations in high-risk early-stage cervical cancer patients treated with postoperative radiation therapy. Sci Rep 2021;11:10567. [PMID: 34012039 DOI: 10.1038/s41598-021-90139-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Zhao J, Galvez C, Beckermann KE, Johnson DB, Sosman JA. Novel insights into the pathogenesis and treatment of NRAS mutant melanoma. Expert Rev Precis Med Drug Dev 2021;6:281-94. [PMID: 34485698 DOI: 10.1080/23808993.2021.1938545] [Reference Citation Analysis]
68 Reese M, Dhayat SA. Small extracellular vesicle non-coding RNAs in pancreatic cancer: molecular mechanisms and clinical implications. J Hematol Oncol 2021;14:141. [PMID: 34496946 DOI: 10.1186/s13045-021-01149-4] [Reference Citation Analysis]
69 Espejo-Freire AP, Elliott A, Rosenberg A, Costa PA, Barreto-Coelho P, Jonczak E, D'Amato G, Subhawong T, Arshad J, Diaz-Perez JA, Korn WM, Oberley MJ, Magee D, Dizon D, von Mehren M, Khushman MM, Hussein AM, Leu K, Trent JC. Genomic Landscape of Angiosarcoma: A Targeted and Immunotherapy Biomarker Analysis. Cancers (Basel) 2021;13:4816. [PMID: 34638300 DOI: 10.3390/cancers13194816] [Reference Citation Analysis]
70 Hayashi H, Uemura N, Zhao L, Matsumura K, Sato H, Shiraishi Y, Baba H. Biological Significance of YAP/TAZ in Pancreatic Ductal Adenocarcinoma. Front Oncol 2021;11:700315. [PMID: 34395269 DOI: 10.3389/fonc.2021.700315] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
71 Araki M, Yoshimoto K, Ohta M, Katada T, Kontani K. Development of a versatile HPLC-based method to evaluate the activation status of small GTPases. J Biol Chem 2021;297:101428. [PMID: 34801548 DOI: 10.1016/j.jbc.2021.101428] [Reference Citation Analysis]
72 Tien JC, Chugh S, Goodrum AE, Cheng Y, Mannan R, Zhang Y, Wang L, Dommeti VL, Wang X, Xu A, Hon J, Kenum C, Su F, Wang R, Cao X, Shankar S, Chinnaiyan AM. AGO2 promotes tumor progression in KRAS-driven mouse models of non-small cell lung cancer. Proc Natl Acad Sci U S A 2021;118:e2026104118. [PMID: 33972443 DOI: 10.1073/pnas.2026104118] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
73 Naim N, Moukheiber S, Daou S, Kourie HR. KRAS-G12C covalent inhibitors: A game changer in the scene of cancer therapies. Crit Rev Oncol Hematol 2021;168:103524. [PMID: 34800654 DOI: 10.1016/j.critrevonc.2021.103524] [Reference Citation Analysis]
74 Minami H, Kiyota N, Kimbara S, Ando Y, Shimokata T, Ohtsu A, Fuse N, Kuboki Y, Shimizu T, Yamamoto N, Nishio K, Kawakami Y, Nihira SI, Sase K, Nonaka T, Takahashi H, Komori Y, Kiyohara K. Guidelines for clinical evaluation of anti-cancer drugs. Cancer Sci 2021;112:2563-77. [PMID: 33990993 DOI: 10.1111/cas.14967] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
75 Oo HZ, Lohinai Z, Khazamipour N, Lo J, Kumar G, Pihl J, Adomat H, Nabavi N, Behmanesh H, Zhai B, Dagil R, Choudhary S, Gustavsson T, Clausen TM, Esko JD, Allen JW, Thompson MA, Tran NL, Moldvay J, Dome B, Salanti A, Al-Nakouzi N, Weiss GJ, Daugaard M. Oncofetal Chondroitin Sulfate Is a Highly Expressed Therapeutic Target in Non-Small Cell Lung Cancer. Cancers (Basel) 2021;13:4489. [PMID: 34503301 DOI: 10.3390/cancers13174489] [Reference Citation Analysis]
76 Bellio H, Fumet JD, Ghiringhelli F. Targeting BRAF and RAS in Colorectal Cancer. Cancers (Basel) 2021;13:2201. [PMID: 34063682 DOI: 10.3390/cancers13092201] [Reference Citation Analysis]
77 Michaelidou K, Koutoulaki C, Mavridis K, Vorrias E, Papadaki MA, Koutsopoulos AV, Mavroudis D, Agelaki S. Detection of KRAS G12/G13 Mutations in Cell Free-DNA by Droplet Digital PCR, Offers Prognostic Information for Patients with Advanced Non-Small Cell Lung Cancer. Cells 2020;9:E2514. [PMID: 33233668 DOI: 10.3390/cells9112514] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
78 Nakayama A, Nagashima T, Nishizono Y, Kuramoto K, Mori K, Homboh K, Yuri M, Shimazaki M. Characterisation of a novel KRAS G12C inhibitor ASP2453 that shows potent anti-tumour activity in KRAS G12C-mutated preclinical models. Br J Cancer 2021. [PMID: 34795410 DOI: 10.1038/s41416-021-01629-x] [Reference Citation Analysis]
79 Singhi EK, Gay CM. Narrative review of the emerging role of molecular biomarkers in guiding the definitive management of unresectable non-small cell lung cancer.Transl Lung Cancer Res. 2020;9:2051-2058. [PMID: 33209625 DOI: 10.21037/tlcr-20-330] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
80 Gregorc V, Lazzari C, Mandalá M, Ippati S, Bulotta A, Cangi MG, Khater A, Viganò MG, Mirabile A, Pecciarini L, Ogliari FR, Arrigoni G, Grassini G, Veronesi G, Doglioni C. Intratumoral Cellular Heterogeneity: Implications for Drug Resistance in Patients with Non-Small Cell Lung Cancer. Cancers (Basel) 2021;13:2023. [PMID: 33922215 DOI: 10.3390/cancers13092023] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
81 Jones NC, Adashek JJ, Ayoub B. Carcinoma of Unknown Primary in a Patient With Lynch Syndrome. Cureus 2021;13:e15690. [PMID: 34159040 DOI: 10.7759/cureus.15690] [Reference Citation Analysis]
82 Okawa Y, Ebata N, Kim NKD, Fujita M, Maejima K, Sasagawa S, Nakamura T, Park WY, Hirano S, Nakagawa H. Actionability evaluation of biliary tract cancer by genome transcriptome analysis and Asian cancer knowledgebase. Oncotarget 2021;12:1540-52. [PMID: 34316332 DOI: 10.18632/oncotarget.28021] [Reference Citation Analysis]
83 Addeo A, Banna GL, Friedlaender A. KRAS G12C Mutations in NSCLC: From Target to Resistance. Cancers (Basel) 2021;13:2541. [PMID: 34064232 DOI: 10.3390/cancers13112541] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
84 de Castro CPM, Cadefau M, Cuartero S. The Mutational Landscape of Myeloid Leukaemia in Down Syndrome. Cancers (Basel) 2021;13:4144. [PMID: 34439298 DOI: 10.3390/cancers13164144] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
85 Murakami M, Fujimori N, Ohno A, Matsumoto K, Teramatsu K, Takamatsu Y, Takeno A, Oono T, Abe T, Ideno N, Ikenaga N, Nakata K, Nakamura M, Ishigami K, Ogawa Y. Predictive factors of operability after neoadjuvant chemotherapy in resectable or borderline resectable pancreatic cancer: a single-center retrospective study. Discov Onc 2022;13. [DOI: 10.1007/s12672-021-00462-1] [Reference Citation Analysis]
86 Ros J, Baraibar I, Martini G, Salvà F, Saoudi N, Cuadra-Urteaga JL, Dienstmann R, Tabernero J, Élez E. The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer. Curr Treat Options Oncol 2021;22:113. [PMID: 34741675 DOI: 10.1007/s11864-021-00913-5] [Reference Citation Analysis]
87 Rohatgi A, Govindan R. Targeting KRAS G12C mutation in lung adenocarcinoma. Lung Cancer 2022;165:28-33. [DOI: 10.1016/j.lungcan.2021.12.021] [Reference Citation Analysis]
88 Akhave NS, Biter AB, Hong DS. Mechanisms of Resistance to KRASG12C-Targeted Therapy. Cancer Discov 2021;11:1345-52. [PMID: 33820777 DOI: 10.1158/2159-8290.CD-20-1616] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
89 Lellouche L, Palmieri LJ, Dermine S, Brezault C, Chaussade S, Coriat R. Systemic therapy in metastatic pancreatic adenocarcinoma: current practice and perspectives. Ther Adv Med Oncol 2021;13:17588359211018539. [PMID: 34285720 DOI: 10.1177/17588359211018539] [Reference Citation Analysis]
90 Serna-Blasco R, Sánchez-Herrero E, Berrocal Renedo M, Calabuig-Fariñas S, Molina-Vila MÁ, Provencio M, Romero A. R-Score: A New Parameter to Assess the Quality of Variants' Calls Assessed by NGS Using Liquid Biopsies. Biology (Basel) 2021;10:954. [PMID: 34681053 DOI: 10.3390/biology10100954] [Reference Citation Analysis]
91 Bolomsky A, Young RM. Pathogenic signaling in multiple myeloma. Seminars in Oncology 2022. [DOI: 10.1053/j.seminoncol.2022.01.005] [Reference Citation Analysis]
92 Tian X, Gu T, Lee MH, Dong Z. Challenge and countermeasures for EGFR targeted therapy in non-small cell lung cancer. Biochim Biophys Acta Rev Cancer 2021;1877:188645. [PMID: 34793897 DOI: 10.1016/j.bbcan.2021.188645] [Reference Citation Analysis]
93 Personeni N, Smiroldo V, Giunta EF, Prete MG, Rimassa L, Bregni G, Sclafani F. Tackling Refractory Metastatic Colorectal Cancer: Future Perspectives. Cancers (Basel) 2021;13:4506. [PMID: 34572729 DOI: 10.3390/cancers13184506] [Reference Citation Analysis]
94 Beatty GL, Werba G, Lyssiotis CA, Simeone DM. The biological underpinnings of therapeutic resistance in pancreatic cancer. Genes Dev 2021;35:940-62. [PMID: 34117095 DOI: 10.1101/gad.348523.121] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
95 da Silva EM, Fix DJ, Sebastiao APM, Selenica P, Ferrando L, Kim SH, Stylianou A, Da Cruz Paula A, Pareja F, Smith ES, Zehir A, Konner JA, Cadoo K, Reis-Filho JS, Abu-Rustum NR, Mueller JJ, Weigelt B, Park KJ. Mesonephric and mesonephric-like carcinomas of the female genital tract: molecular characterization including cases with mixed histology and matched metastases. Mod Pathol 2021;34:1570-87. [PMID: 33772212 DOI: 10.1038/s41379-021-00799-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
96 Nagasaka M, Potugari B, Nguyen A, Sukari A, Azmi AS, Ou SI. KRAS Inhibitors- yes but what next? Direct targeting of KRAS- vaccines, adoptive T cell therapy and beyond. Cancer Treat Rev 2021;101:102309. [PMID: 34715449 DOI: 10.1016/j.ctrv.2021.102309] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
97 Xie M, Xu X, Fan Y. KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup. Front Oncol 2021;11:672612. [PMID: 34012925 DOI: 10.3389/fonc.2021.672612] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
98 Cimino SK, Eng C. Up-and-Coming Experimental Drug Options for Metastatic Colorectal Cancer. J Exp Pharmacol 2020;12:475-85. [PMID: 33204182 DOI: 10.2147/JEP.S259287] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
99 Zhao Y, Wang S, Yang Z, Dong Y, Wang Y, Zhang L, Hu H, Han B. Co-Occurring Potentially Actionable Oncogenic Drivers in Non-Small Cell Lung Cancer. Front Oncol 2021;11:665484. [PMID: 34221980 DOI: 10.3389/fonc.2021.665484] [Reference Citation Analysis]
100 Es HA, Mahdizadeh H, Asl AAH, Totonchi M. Genomic alterations and possible druggable mutations in carcinoma of unknown primary (CUP). Sci Rep 2021;11:15112. [PMID: 34302033 DOI: 10.1038/s41598-021-94678-4] [Reference Citation Analysis]
101 Taha T, Khoury R, Brenner R, Nasrallah H, Shofaniyeh I, Yousef S, Agbarya A. Treatment of Rare Mutations in Patients with Lung Cancer. Biomedicines 2021;9:534. [PMID: 34064757 DOI: 10.3390/biomedicines9050534] [Reference Citation Analysis]
102 Fakih MG, Kopetz S, Kuboki Y, Kim TW, Munster PN, Krauss JC, Falchook GS, Han SW, Heinemann V, Muro K, Strickler JH, Hong DS, Denlinger CS, Girotto G, Lee MA, Henary H, Tran Q, Park JK, Ngarmchamnanrith G, Prenen H, Price TJ. Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial. Lancet Oncol 2022;23:115-24. [PMID: 34919824 DOI: 10.1016/S1470-2045(21)00605-7] [Reference Citation Analysis]
103 Lin JJ, Choudhury NJ, Yoda S, Zhu VW, Johnson TW, Sakhtemani R, Dagogo-Jack I, Digumarthy SR, Lee C, Do A, Peterson J, Prutisto-Chang K, Malik W, Hubbeling HG, Langenbucher A, Schoenfeld AJ, Falcon CJ, Temel JS, Sequist LV, Yeap BY, Lennerz JK, Shaw AT, Lawrence MS, Ou SI, Hata AN, Drilon A, Gainor JF. Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer. Clin Cancer Res 2021;27:2899-909. [PMID: 33685866 DOI: 10.1158/1078-0432.CCR-21-0032] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
104 Rahman S, Garrel S, Gerber M, Maitra R, Goel S. Therapeutic Targets of KRAS in Colorectal Cancer. Cancers (Basel) 2021;13:6233. [PMID: 34944853 DOI: 10.3390/cancers13246233] [Reference Citation Analysis]
105 Gutiontov SI, Turchan WT, Spurr LF, Rouhani SJ, Chervin CS, Steinhardt G, Lager AM, Wanjari P, Malik R, Connell PP, Chmura SJ, Juloori A, Hoffman PC, Ferguson MK, Donington JS, Patel JD, Vokes EE, Weichselbaum RR, Bestvina CM, Segal JP, Pitroda SP. CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer. Sci Rep 2021;11:20059. [PMID: 34625620 DOI: 10.1038/s41598-021-99524-1] [Reference Citation Analysis]
106 Wang S, Zheng Y, Yang F, Zhu L, Zhu XQ, Wang ZF, Wu XL, Zhou CH, Yan JY, Hu BY, Kong B, Fu DL, Bruns C, Zhao Y, Qin LX, Dong QZ. The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives. Signal Transduct Target Ther 2021;6:249. [PMID: 34219130 DOI: 10.1038/s41392-021-00659-4] [Reference Citation Analysis]
107 Kato S. Tumour-Agnostic Therapy for Pancreatic Cancer and Biliary Tract Cancer. Diagnostics (Basel) 2021;11:252. [PMID: 33562094 DOI: 10.3390/diagnostics11020252] [Reference Citation Analysis]
108 Özdoğan M, Papadopoulou E, Tsoulos N, Tsantikidi A, Mariatou VM, Tsaousis G, Kapeni E, Bourkoula E, Fotiou D, Kapetsis G, Boukovinas I, Touroutoglou N, Fassas A, Adamidis A, Kosmidis P, Trafalis D, Galani E, Lypas G, Orhan B, Tansan S, Özatlı T, Kırca O, Çakır O, Nasioulas G. Comprehensive tumor molecular profile analysis in clinical practice. BMC Med Genomics 2021;14:105. [PMID: 33853586 DOI: 10.1186/s12920-021-00952-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
109 Merz V, Gaule M, Zecchetto C, Cavaliere A, Casalino S, Pesoni C, Contarelli S, Sabbadini F, Bertolini M, Mangiameli D, Milella M, Fedele V, Melisi D. Targeting KRAS: The Elephant in the Room of Epithelial Cancers. Front Oncol 2021;11:638360. [PMID: 33777798 DOI: 10.3389/fonc.2021.638360] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
110 Liu T, Zhou L, He Z, Chen Y, Jiang X, Xu J, Jiang J. Circular RNA hsa_circ_0006117 Facilitates Pancreatic Cancer Progression by Regulating the miR-96-5p/KRAS/MAPK Signaling Pathway. J Oncol 2021;2021:9213205. [PMID: 34512755 DOI: 10.1155/2021/9213205] [Reference Citation Analysis]
111 Aran V. K-RAS4A: Lead or Supporting Role in Cancer Biology? Front Mol Biosci 2021;8:729830. [PMID: 34604308 DOI: 10.3389/fmolb.2021.729830] [Reference Citation Analysis]
112 Scarborough JA, Scott JG. Translation of Precision Medicine Research Into Biomarker-Informed Care in Radiation Oncology. Semin Radiat Oncol 2022;32:42-53. [PMID: 34861995 DOI: 10.1016/j.semradonc.2021.09.001] [Reference Citation Analysis]
113 Bansod S, Dodhiawala PB, Lim KH. Oncogenic KRAS-Induced Feedback Inflammatory Signaling in Pancreatic Cancer: An Overview and New Therapeutic Opportunities. Cancers (Basel) 2021;13:5481. [PMID: 34771644 DOI: 10.3390/cancers13215481] [Reference Citation Analysis]
114 Meng F, Lu L, Tan Y, Duan Q, Lu H. Case Report: A Pancreatic Ductal Adenocarcinoma Patient With Concurrent Targetable Somatic Novel KANK1-ALK, UPP2-NTRK3 Fusion, and Pathogenetic Germline BRCA Mutation. Front Oncol 2021;11:757965. [PMID: 34671564 DOI: 10.3389/fonc.2021.757965] [Reference Citation Analysis]
115 Tang D, Kroemer G, Kang R. Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges. Mol Cancer 2021;20:128. [PMID: 34607583 DOI: 10.1186/s12943-021-01422-7] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
116 Deng Y, Xia X, Zhao Y, Zhao Z, Martinez C, Yin W, Yao J, Hang Q, Wu W, Zhang J, Yu Y, Xia W, Yao F, Zhao D, Sun Y, Ying H, Hung MC, Ma L. Glucocorticoid receptor regulates PD-L1 and MHC-I in pancreatic cancer cells to promote immune evasion and immunotherapy resistance. Nat Commun 2021;12:7041. [PMID: 34873175 DOI: 10.1038/s41467-021-27349-7] [Reference Citation Analysis]
117 Yu C, Luo D, Yu J, Zhang M, Zheng X, Xu G, Wang J, Wang H, Xu Y, Jiang K, Xu J, Ma X, Jing J, Shi H. Genome-wide CRISPR-cas9 knockout screening identifies GRB7 as a driver for MEK inhibitor resistance in KRAS mutant colon cancer. Oncogene 2021. [PMID: 34718347 DOI: 10.1038/s41388-021-02077-w] [Reference Citation Analysis]
118 Li K, Zheng X, Tang H, Zang YS, Zeng C, Liu X, Shen Y, Pang Y, Wang S, Xie F, Lu X, Luo Y, Li Z, Bi W, Jia X, Huang T, Wei R, Huang K, Chen Z, Zhu Q, He Y, Zhang M, Gu Z, Xiao Y, Zhang X, Fletcher JA, Wang Y. E3 ligase MKRN3 is a tumor suppressor regulating PABPC1 ubiquitination in non-small cell lung cancer. J Exp Med 2021;218:e20210151. [PMID: 34143182 DOI: 10.1084/jem.20210151] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
119 Zeng JH, Liu YX, Yuan J, Wang FX, Wu WB, Li JX, Wang LF, Gao H, Wang Y, Dong CF, Li YJ, Xie XJ, Feng C, Liu L. First case of COVID-19 complicated with fulminant myocarditis: a case report and insights. Infection 2020;48:773-7. [PMID: 32277408 DOI: 10.1007/s15010-020-01424-5] [Cited by in Crossref: 197] [Cited by in F6Publishing: 225] [Article Influence: 98.5] [Reference Citation Analysis]
120 Molina-Arcas M, Samani A, Downward J. Drugging the Undruggable: Advances on RAS Targeting in Cancer. Genes (Basel) 2021;12:899. [PMID: 34200676 DOI: 10.3390/genes12060899] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
121 Spella M, Stathopoulos GT. Immune Resistance in Lung Adenocarcinoma. Cancers (Basel) 2021;13:384. [PMID: 33494181 DOI: 10.3390/cancers13030384] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
122 Cherri S, Libertini M, Zaniboni A. New drugs for the treatment of metastatic colorectal cancer. World J Gastrointest Oncol 2021; 13(11): 1551-1560 [PMID: 34853636 DOI: 10.4251/wjgo.v13.i11.1551] [Reference Citation Analysis]
123 Aplin AE, Capparelli C. Combined SHPments: An Effective Therapeutic Strategy for MPNST. Cancer Res 2021;81:266-7. [PMID: 33452215 DOI: 10.1158/0008-5472.CAN-20-3834] [Reference Citation Analysis]
124 Mickler EA, Zhou H, Phang TL, Geraci MW, Stearman RS, Sears CR. Low-Coverage Whole Genome Sequencing Using Laser Capture Microscopy with Combined Digital Droplet PCR: An Effective Tool to Study Copy Number and Kras Mutations in Early Lung Adenocarcinoma Development. Int J Mol Sci 2021;22:12034. [PMID: 34769463 DOI: 10.3390/ijms222112034] [Reference Citation Analysis]
125 Jang YJ, Hyun DG, Choi CM, Lee DH, Kim SW, Yoon S, Kim WS, Ji W, Lee JC. Optimizing palliative chemotherapy for advanced invasive mucinous adenocarcinoma of the lung. BMC Cancer 2021;21:731. [PMID: 34174841 DOI: 10.1186/s12885-021-08472-6] [Reference Citation Analysis]
126 Kwan AK, Piazza GA, Keeton AB, Leite CA. The path to the clinic: a comprehensive review on direct KRASG12C inhibitors. J Exp Clin Cancer Res 2022;41. [DOI: 10.1186/s13046-021-02225-w] [Reference Citation Analysis]
127 Chang JC, Offin M, Falcon C, Brown D, Houck-Loomis BR, Meng F, Rudneva VA, Won HH, Amir S, Montecalvo J, Desmeules P, Kadota K, Adusumilli PS, Rusch VW, Teed S, Sabari JK, Benayed R, Nafa K, Borsu L, Li BT, Schram AM, Arcila ME, Travis WD, Ladanyi M, Drilon A, Rekhtman N. Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes. Clin Cancer Res 2021;27:4066-76. [PMID: 33947695 DOI: 10.1158/1078-0432.CCR-21-0423] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
128 Lee JJ, Jain V, Amaravadi RK. Clinical Translation of Combined MAPK and Autophagy Inhibition in RAS Mutant Cancer. Int J Mol Sci 2021;22:12402. [PMID: 34830283 DOI: 10.3390/ijms222212402] [Reference Citation Analysis]
129 Cao D, Song Q, Li J, Jiang Y, Wang Z, Lu S. Opportunities and challenges in targeted therapy and immunotherapy for pancreatic cancer. Expert Rev Mol Med 2021;23:e21. [PMID: 34906271 DOI: 10.1017/erm.2021.26] [Reference Citation Analysis]
130 Vassella E, Kashani E, Zens P, Kündig A, Fung C, Scherz A, Herrmann E, Ermis E, Schmid RA, Berezowska S. Mutational profiles of primary pulmonary adenocarcinoma and paired brain metastases disclose the importance of KRAS mutations. Eur J Cancer 2021;159:227-36. [PMID: 34781171 DOI: 10.1016/j.ejca.2021.10.006] [Reference Citation Analysis]
131 Zhao Y, Murciano-Goroff YR, Xue JY, Ang A, Lucas J, Mai TT, Da Cruz Paula AF, Saiki AY, Mohn D, Achanta P, Sisk AE, Arora KS, Roy RS, Kim D, Li C, Lim LP, Li M, Bahr A, Loomis BR, de Stanchina E, Reis-Filho JS, Weigelt B, Berger M, Riely G, Arbour KC, Lipford JR, Li BT, Lito P. Diverse alterations associated with resistance to KRAS(G12C) inhibition. Nature 2021;599:679-83. [PMID: 34759319 DOI: 10.1038/s41586-021-04065-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
132 Khaddour K, Maahs L, Avila-Rodriguez AM, Maamar Y, Samaan S, Ansstas G. Melanoma Targeted Therapies beyond BRAF-Mutant Melanoma: Potential Druggable Mutations and Novel Treatment Approaches. Cancers (Basel) 2021;13:5847. [PMID: 34831002 DOI: 10.3390/cancers13225847] [Reference Citation Analysis]
133 Imaoka H, Sasaki M, Hashimoto Y, Watanabe K, Miyazawa S, Shibuki T, Mitsunaga S, Ikeda M. Impact of Endoscopic Ultrasound-Guided Tissue Acquisition on Decision-Making in Precision Medicine for Pancreatic Cancer: Beyond Diagnosis. Diagnostics (Basel) 2021;11:1195. [PMID: 34209310 DOI: 10.3390/diagnostics11071195] [Reference Citation Analysis]
134 Guo H, Li W, Wang B, Chen N, Qian L, Cui J. Coexisting opportunities and challenges: In which scenarios can minimal/measurable residual disease play a role in advanced non-small cell lung cancer? Chin J Cancer Res 2021;33:574-82. [PMID: 34815631 DOI: 10.21147/j.issn.1000-9604.2021.05.04] [Reference Citation Analysis]
135 Zhang J, Zhang J, Liu Q, Fan XX, Leung EL, Yao XJ, Liu L. Resistance looms for KRAS G12C inhibitors and rational tackling strategies. Pharmacol Ther 2021;229:108050. [PMID: 34864132 DOI: 10.1016/j.pharmthera.2021.108050] [Reference Citation Analysis]
136 Rohrberg KS, Lassen U. Detecting and Targeting NTRK Fusions in Cancer in the Era of Tumor Agnostic Oncology. Drugs 2021;81:445-52. [PMID: 33400240 DOI: 10.1007/s40265-020-01459-w] [Reference Citation Analysis]
137 Tani T, Kitajima S, Conway EB, Knelson EH, Barbie DA. KRAS G12C inhibition and innate immune targeting. Expert Opin Ther Targets 2021;25:167-74. [PMID: 33703985 DOI: 10.1080/14728222.2021.1902991] [Reference Citation Analysis]
138 Zhao Y, Wang H, He C. Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy. J Cancer Res Clin Oncol 2021;147:3653-64. [PMID: 34661758 DOI: 10.1007/s00432-021-03828-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
139 Coleman N, Hong L, Zhang J, Heymach J, Hong D, Le X. Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer. ESMO Open 2021;6:100319. [PMID: 34837746 DOI: 10.1016/j.esmoop.2021.100319] [Reference Citation Analysis]
140 Ritu K, Kumar P, Singh A, Nupur K, Spalgias S, Mrigpuri P, Rajkumar. Untangling the KRAS mutated lung cancer subsets and its therapeutic implications. Mol Biomed 2021;2. [DOI: 10.1186/s43556-021-00061-0] [Reference Citation Analysis]
141 Chen X, Zeh HJ, Kang R, Kroemer G, Tang D. Cell death in pancreatic cancer: from pathogenesis to therapy. Nat Rev Gastroenterol Hepatol 2021. [PMID: 34331036 DOI: 10.1038/s41575-021-00486-6] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
142 Skribek M, Rounis K, Tsakonas G, Ekman S. Complications following novel therapies for non-small cell lung cancer. J Intern Med 2022. [PMID: 35032058 DOI: 10.1111/joim.13445] [Reference Citation Analysis]
143 Huang L, Guo Z, Wang F, Fu L. KRAS mutation: from undruggable to druggable in cancer. Signal Transduct Target Ther 2021;6:386. [PMID: 34776511 DOI: 10.1038/s41392-021-00780-4] [Reference Citation Analysis]
144 Knight JRP, Alexandrou C, Skalka GL, Vlahov N, Pennel K, Officer L, Teodosio A, Kanellos G, Gay DM, May-Wilson S, Smith EM, Najumudeen AK, Gilroy K, Ridgway RA, Flanagan DJ, Smith RCL, McDonald L, MacKay C, Cheasty A, McArthur K, Stanway E, Leach JD, Jackstadt R, Waldron JA, Campbell AD, Vlachogiannis G, Valeri N, Haigis KM, Sonenberg N, Proud CG, Jones NP, Swarbrick ME, McKinnon HJ, Faller WJ, Le Quesne J, Edwards J, Willis AE, Bushell M, Sansom OJ. MNK Inhibition Sensitizes KRAS-Mutant Colorectal Cancer to mTORC1 Inhibition by Reducing eIF4E Phosphorylation and c-MYC Expression. Cancer Discov 2021;11:1228-47. [PMID: 33328217 DOI: 10.1158/2159-8290.CD-20-0652] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
145 Dunnett-Kane V, Nicola P, Blackhall F, Lindsay C. Mechanisms of Resistance to KRASG12C Inhibitors. Cancers (Basel) 2021;13:E151. [PMID: 33466360 DOI: 10.3390/cancers13010151] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
146 Riedesser JE, Ebert MP, Betge J. Precision medicine for metastatic colorectal cancer in clinical practice. Ther Adv Med Oncol 2022;14:175883592110727. [DOI: 10.1177/17588359211072703] [Reference Citation Analysis]
147 Marin E, Reyes R, Arcocha A, Viñolas N, Mezquita L, Gonzalvo E, Saez de Gordoa K, Jares P, Reguart N, Teixido C. Prospective Evaluation of Single Nucleotide Variants by Two Different Technologies in Paraffin Samples of Advanced Non-Small Cell Lung Cancer Patients. Diagnostics (Basel) 2020;10:E902. [PMID: 33153192 DOI: 10.3390/diagnostics10110902] [Reference Citation Analysis]
148 Liu J, Kang R, Tang D. The KRAS-G12C inhibitor: activity and resistance. Cancer Gene Ther 2021. [PMID: 34471232 DOI: 10.1038/s41417-021-00383-9] [Reference Citation Analysis]
149 East MP, Johnson GL. Adaptive chromatin remodeling and transcriptional changes of the functional kinome in tumor cells in response to targeted kinase inhibition. J Biol Chem 2021;:101525. [PMID: 34958800 DOI: 10.1016/j.jbc.2021.101525] [Reference Citation Analysis]
150 Knight JR, Vlahov N, Gay DM, Ridgway RA, Faller WJ, Proud C, Mallucci GR, von der Haar T, Smales CM, Willis AE, Sansom OJ. Rpl24Bst mutation suppresses colorectal cancer by promoting eEF2 phosphorylation via eEF2K. Elife 2021;10:e69729. [PMID: 34895463 DOI: 10.7554/eLife.69729] [Reference Citation Analysis]
151 Akhoundova D, Mosquera Martinez J, Musmann LE, Britschgi C, Rütsche C, Rechsteiner M, Nadal E, Garcia Campelo MR, Curioni-Fontecedro A. The Role of the Liquid Biopsy in Decision-Making for Patients with Non-Small Cell Lung Cancer. J Clin Med 2020;9:E3674. [PMID: 33207619 DOI: 10.3390/jcm9113674] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
152 Lengel HB, Connolly JG, Jones GD, Caso R, Zhou J, Sanchez-Vega F, Mastrogiacomo B, Isbell JM, Li BT, Liu Y, Rekhtman N, Jones DR. The Emerging Importance of Tumor Genomics in Operable Non-Small Cell Lung Cancer. Cancers (Basel) 2021;13:3656. [PMID: 34359558 DOI: 10.3390/cancers13153656] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
153 Jørgensen JT. Oncology drug-companion diagnostic combinations. Cancer Treat Res Commun 2021;29:100492. [PMID: 34844911 DOI: 10.1016/j.ctarc.2021.100492] [Reference Citation Analysis]
154 Amodio V, Mauri G, Reilly NM, Sartore-Bianchi A, Siena S, Bardelli A, Germano G. Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers. Cancers (Basel) 2021;13:2638. [PMID: 34072037 DOI: 10.3390/cancers13112638] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
155 Tanaka N, Lin JJ, Li C, Ryan MB, Zhang J, Kiedrowski LA, Michel AG, Syed MU, Fella KA, Sakhi M, Baiev I, Juric D, Gainor JF, Klempner SJ, Lennerz JK, Siravegna G, Bar-Peled L, Hata AN, Heist RS, Corcoran RB. Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation. Cancer Discov 2021;11:1913-22. [PMID: 33824136 DOI: 10.1158/2159-8290.CD-21-0365] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
156 D'Angelo A, Sobhani N, Chapman R, Bagby S, Bortoletti C, Traversini M, Ferrari K, Voltolini L, Darlow J, Roviello G. Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies. Cancers (Basel) 2020;12:E3293. [PMID: 33172113 DOI: 10.3390/cancers12113293] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
157 Luo J. KRAS mutation in pancreatic cancer. Semin Oncol 2021:S0093-7754(21)00008-7. [PMID: 33676749 DOI: 10.1053/j.seminoncol.2021.02.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
158 Okafor C, Hogan J, Raygada M, Thomas BJ, Akshintala S, Glod JW, Del Rivero J. Update on Targeted Therapy in Medullary Thyroid Cancer. Front Endocrinol (Lausanne) 2021;12:708949. [PMID: 34489865 DOI: 10.3389/fendo.2021.708949] [Reference Citation Analysis]
159 John L, Krauth MT, Podar K, Raab MS. Pathway-Directed Therapy in Multiple Myeloma. Cancers (Basel) 2021;13:1668. [PMID: 33916289 DOI: 10.3390/cancers13071668] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
160 Bayle A, Basile D, Garinet S, Rance B, Laurent-Puig P, Blons H, Taieb J, Perkins G. Next-Generation Sequencing Targeted Panel in Routine Care for Metastatic Colon Cancers. Cancers (Basel) 2021;13:5750. [PMID: 34830904 DOI: 10.3390/cancers13225750] [Reference Citation Analysis]
161 Lee MKC, Grimmond SM, McArthur GA, Sheppard KE. PRMT5: An Emerging Target for Pancreatic Adenocarcinoma. Cancers (Basel) 2021;13:5136. [PMID: 34680285 DOI: 10.3390/cancers13205136] [Reference Citation Analysis]
162 Ikoma T, Shimokawa M, Kotaka M, Matsumoto T, Nagai H, Boku S, Shibata N, Yasui H, Satake H. Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan. BMC Cancer 2021;21:518. [PMID: 33962575 DOI: 10.1186/s12885-021-08271-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
163 Kim MJ, Chang H, Nam G, Ko Y, Kim SH, Roberts TM, Ryu JH. RNAi-Based Approaches for Pancreatic Cancer Therapy. Pharmaceutics 2021;13:1638. [PMID: 34683931 DOI: 10.3390/pharmaceutics13101638] [Reference Citation Analysis]
164 Rosati G, Aprile G, Basile D, Avallone A. Perspectives in the Treatment of RAS or BRAF Mutated Metastatic Colorectal Cancer Patients. Front Oncol 2021;11:602596. [PMID: 33738249 DOI: 10.3389/fonc.2021.602596] [Reference Citation Analysis]
165 Devarakonda S, Pellini B, Verghese L, Park H, Morgensztern D, Govindan R, Suresh R, Oppelt P, Baggstrom MQ, Wu N, Waqar SN. A phase II study of everolimus in patients with advanced solid malignancies with TSC1, TSC2, NF1, NF2 or STK11 mutations. J Thorac Dis 2021;13:4054-62. [PMID: 34422335 DOI: 10.21037/jtd-21-195] [Reference Citation Analysis]
166 Bourhis A, Remoué A, Samaison L, Uguen A. Diagnostic mutationnel rapide Idylla™ : applications théranostiques actuelles et futures. Annales de Pathologie 2022. [DOI: 10.1016/j.annpat.2021.12.007] [Reference Citation Analysis]
167 Taniguchi F, Nyuya A, Toshima T, Yasui K, Mori Y, Okawaki M, Kishimoto H, Umeda Y, Fujiwara T, Tanioka H, Yamaguchi Y, Goel A, Nagasaka T. Concordance of acquired mutations between metastatic lesions and liquid biopsy in metastatic colorectal cancer. Future Sci OA 2021;7:FSO757. [PMID: 34840814 DOI: 10.2144/fsoa-2021-0059] [Reference Citation Analysis]
168 Le X, Hong L, Hensel C, Chen R, Kemp H, Coleman N, Ciunci CA, Liu SV, Negrao MV, Yen J, Xia X, Scheuenpflug J, Stroh C, Juraeva D, Tsao A, Hong D, Raymond V, Paik P, Zhang J, Heymach JV. Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non-Small-Cell Lung Cancer Harboring MET Exon 14 Skipping. JCO Precis Oncol 2021;5:PO. [PMID: 34957368 DOI: 10.1200/PO.21.00135] [Reference Citation Analysis]
169 Padmanabhan J, Saha B, Powell C, Mo Q, Perez BA, Chellappan S. Inhibitors Targeting CDK9 Show High Efficacy against Osimertinib and AMG510 Resistant Lung Adenocarcinoma Cells. Cancers (Basel) 2021;13:3906. [PMID: 34359807 DOI: 10.3390/cancers13153906] [Reference Citation Analysis]
170 Coleman N, Rodon J. Taking Aim at the Undruggable. Am Soc Clin Oncol Educ Book 2021;41:1-8. [PMID: 33989024 DOI: 10.1200/EDBK_325885] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
171 Cavagna R, Escremim de Paula F, Sant'Anna D, Santana I, da Silva VD, da Silva ECA, Bacchi CE, Miziara JE, Dias JM, De Marchi P, Leal LF, Reis RM. Frequency of KRAS p.Gly12Cys Mutation in Brazilian Patients With Lung Cancer. JCO Glob Oncol 2021;7:639-45. [PMID: 33956502 DOI: 10.1200/GO.20.00615] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
172 Stein MK, Oluoha O, Patel K, VanderWalde A. Precision Medicine in Oncology: A Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer. J Pers Med 2021;11:518. [PMID: 34198738 DOI: 10.3390/jpm11060518] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
173 Henry JT, Coker O, Chowdhury S, Shen JP, Morris VK, Dasari A, Raghav K, Nusrat M, Kee B, Parseghian C, Pant S, Jeyakumar N, Zhu L, Nishioka Y, Fogelman D, Wolff RA, Hong D, Overman MJ, Vauthey J, Kopetz S, Johnson B. Comprehensive Clinical and Molecular Characterization of KRAS G12C-Mutant Colorectal Cancer. JCO Precis Oncol 2021;5:PO. [PMID: 34250391 DOI: 10.1200/PO.20.00256] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
174 Imyanitov E, Kuligina E. Molecular testing for colorectal cancer: Clinical applications. World J Gastrointest Oncol 2021; 13(10): 1288-1301 [PMID: 34721767 DOI: 10.4251/wjgo.v13.i10.1288] [Reference Citation Analysis]
175 Serna-Blasco R, Sánchez-Herrero E, Sanz-Moreno S, Rodriguez-Festa A, García-Veros E, Casarrubios M, Sierra-Rodero B, Laza-Briviesca R, Cruz-Bermúdez A, Mielgo-Rubio X, Sánchez-Hernández A, Uribelarrea EA, Calvo V, Romero A, Provencio M. KRAS p.G12C mutation occurs in 1% of EGFR-mutated advanced non-small-cell lung cancer patients progressing on a first-line treatment with a tyrosine kinase inhibitor. ESMO Open 2021;6:100279. [PMID: 34607284 DOI: 10.1016/j.esmoop.2021.100279] [Reference Citation Analysis]
176 Ratain MJ, Tannock IF, Lichter AS. Dose Optimization of Sotorasib: Is the US Food and Drug Administration Sending a Message? J Clin Oncol 2021;39:3423-6. [PMID: 34543056 DOI: 10.1200/JCO.21.01371] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
177 Kankeu Fonkoua LA, Serrano Uson Junior PL, Mody K, Mahipal A, Borad MJ, Roberts LR. Novel and emerging targets for cholangiocarcinoma progression: therapeutic implications. Expert Opin Ther Targets 2022. [PMID: 35034558 DOI: 10.1080/14728222.2022.2029412] [Reference Citation Analysis]
178 Sun G, Rong D, Li Z, Sun G, Wu F, Li X, Cao H, Cheng Y, Tang W, Sun Y. Role of Small Molecule Targeted Compounds in Cancer: Progress, Opportunities, and Challenges. Front Cell Dev Biol 2021;9:694363. [PMID: 34568317 DOI: 10.3389/fcell.2021.694363] [Reference Citation Analysis]
179 Dantoing E, Piton N, Salaün M, Thiberville L, Guisier F. Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations. Int J Mol Sci 2021;22:6288. [PMID: 34208111 DOI: 10.3390/ijms22126288] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
180 Chen K, Zhang Y, Qian L, Wang P. Emerging strategies to target RAS signaling in human cancer therapy. J Hematol Oncol 2021;14:116. [PMID: 34301278 DOI: 10.1186/s13045-021-01127-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
181 Lauko A, Kotecha R, Barnett A, Li H, Tatineni V, Ali A, Patil P, Mohammadi AM, Chao ST, Murphy ES, Angelov L, Suh JH, Barnett GH, Pennell NA, Ahluwalia MS. Impact of KRAS mutation status on the efficacy of immunotherapy in lung cancer brain metastases. Sci Rep 2021;11:18174. [PMID: 34518623 DOI: 10.1038/s41598-021-97566-z] [Reference Citation Analysis]
182 Palma G, Khurshid F, Lu K, Woodward B, Husain H. Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes. NPJ Precis Oncol 2021;5:98. [PMID: 34845311 DOI: 10.1038/s41698-021-00237-5] [Reference Citation Analysis]
183 Coleman N, Harbery A, Heuss S, Vivanco I, Popat S. Targeting un-MET needs in advanced non-small cell lung cancer. Lung Cancer 2021;164:56-68. [PMID: 35033939 DOI: 10.1016/j.lungcan.2021.12.016] [Reference Citation Analysis]
184 Xu Z, Hu K, Bailey P, Springfeld C, Roth S, Kurilov R, Brors B, Gress T, Buchholz M, An J, Wei K, Peccerella T, Büchler MW, Hackert T, Neoptolemos JP. Clinical Impact of Molecular Subtyping of Pancreatic Cancer. Front Cell Dev Biol 2021;9:743908. [PMID: 34805152 DOI: 10.3389/fcell.2021.743908] [Reference Citation Analysis]
185 Zheng-Lin B, O'Reilly EM. Pancreatic ductal adenocarcinoma in the era of precision medicine. Semin Oncol 2021:S0093-7754(21)00005-1. [PMID: 33637355 DOI: 10.1053/j.seminoncol.2021.01.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
186 Amoedo ND, Sarlak S, Obre E, Esteves P, Bégueret H, Kieffer Y, Rousseau B, Dupis A, Izotte J, Bellance N, Dard L, Redonnet-Vernhet I, Punzi G, Rodrigues MF, Dumon E, Mafhouf W, Guyonnet-Dupérat V, Gales L, Palama T, Bellvert F, Dugot-Senan N, Claverol S, Baste JM, Lacombe D, Rezvani HR, Pierri CL, Mechta-Grigoriou F, Thumerel M, Rossignol R. Targeting the mitochondrial trifunctional protein restrains tumor growth in oxidative lung carcinomas. J Clin Invest 2021;131:133081. [PMID: 33393495 DOI: 10.1172/JCI133081] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
187 Nussinov R, Jang H, Gursoy A, Keskin O, Gaponenko V. Inhibition of Nonfunctional Ras. Cell Chem Biol 2021;28:121-33. [PMID: 33440168 DOI: 10.1016/j.chembiol.2020.12.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
188 Chen X, Kang R, Kroemer G, Tang D. Broadening horizons: the role of ferroptosis in cancer. Nat Rev Clin Oncol. 2021;. [PMID: 33514910 DOI: 10.1038/s41571-020-00462-0] [Cited by in Crossref: 48] [Cited by in F6Publishing: 68] [Article Influence: 48.0] [Reference Citation Analysis]
189 Shuford RA, Cairns AL, Moaven O. Precision Approaches in the Management of Colorectal Cancer: Current Evidence and Latest Advancements Towards Individualizing the Treatment. Cancers (Basel) 2020;12:E3481. [PMID: 33238500 DOI: 10.3390/cancers12113481] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
190 Roosan MR, Mambetsariev I, Pharaon R, Fricke J, Baroz AR, Chao J, Chen C, Nasser MW, Chirravuri-Venkata R, Jain M, Smith L, Yost SE, Reckamp KL, Pillai R, Arvanitis L, Afkhami M, Wang EW, Chung V, Cristea M, Fakih M, Koczywas M, Massarelli E, Mortimer J, Yuan Y, Batra SK, Pal S, Salgia R. Evaluation of Somatic Mutations in Solid Metastatic Pan-Cancer Patients. Cancers (Basel) 2021;13:2776. [PMID: 34204917 DOI: 10.3390/cancers13112776] [Reference Citation Analysis]
191 Salgia R, Pharaon R, Mambetsariev I, Nam A, Sattler M. The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC). Cell Rep Med 2021;2:100186. [PMID: 33521700 DOI: 10.1016/j.xcrm.2020.100186] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
192 Bender G, Fahrioglu Yamaci R, Taneri B. CRISPR and KRAS: a match yet to be made. J Biomed Sci 2021;28:77. [PMID: 34781949 DOI: 10.1186/s12929-021-00772-0] [Reference Citation Analysis]
193 Zhu G, Pei L, Xia H, Tang Q, Bi F. Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer. Mol Cancer 2021;20:143. [PMID: 34742312 DOI: 10.1186/s12943-021-01441-4] [Reference Citation Analysis]
194 van Maldegem F, Valand K, Cole M, Patel H, Angelova M, Rana S, Colliver E, Enfield K, Bah N, Kelly G, Tsang VSK, Mugarza E, Moore C, Hobson P, Levi D, Molina-Arcas M, Swanton C, Downward J. Characterisation of tumour microenvironment remodelling following oncogene inhibition in preclinical studies with imaging mass cytometry. Nat Commun 2021;12:5906. [PMID: 34625563 DOI: 10.1038/s41467-021-26214-x] [Reference Citation Analysis]
195 Alawawdeh A, Piantadosi C, Townsend AR, Karapetis CS, Padbury R, Roy AC, Moore J, Maddern G, Roder D, Smith A, Price TJ. Prognostic Differences of RAS Mutations: Results from the South Australian Metastatic Colorectal Registry. Target Oncol 2021. [PMID: 34822070 DOI: 10.1007/s11523-021-00856-9] [Reference Citation Analysis]
196 Nagayama S, Low SK, Kiyotani K, Nakamura Y. Precision Medicine for Colorectal Cancer with Liquid Biopsy and Immunotherapy. Cancers (Basel) 2021;13:4803. [PMID: 34638288 DOI: 10.3390/cancers13194803] [Reference Citation Analysis]
197 Chen K, Wu S, Ye S, Huang H, Zhou Y, Zhou H, Wu S, Mao Y, Shangguan F, Lan L, Chen B. Dimethyl Fumarate Induces Metabolic Crisie to Suppress Pancreatic Carcinoma. Front Pharmacol 2021;12:617714. [PMID: 33692690 DOI: 10.3389/fphar.2021.617714] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
198 Hayashi A, Hong J, Iacobuzio-Donahue CA. The pancreatic cancer genome revisited. Nat Rev Gastroenterol Hepatol 2021;18:469-81. [PMID: 34089011 DOI: 10.1038/s41575-021-00463-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
199 Grozavu I, Stuart S, Lyakisheva A, Yao Z, Pathmanathan S, Ohh M, Stagljar I. D154Q Mutation does not Alter KRAS Dimerization. J Mol Biol 2021;434:167392. [PMID: 34896362 DOI: 10.1016/j.jmb.2021.167392] [Reference Citation Analysis]
200 Choi S, Kim SW, Kim HS. Invasive Stratified Mucin-producing Carcinoma (ISMC) of the Uterine Cervix: Clinicopathological and Molecular Characteristics With Special Emphasis on the First Description of Consistent Programmed Death-ligand 1 (PD-L1) Over-expression. Cancer Genomics Proteomics 2021;18:685-98. [PMID: 34479920 DOI: 10.21873/cgp.20290] [Reference Citation Analysis]